AIM
FPRX

Advantage Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Advantage Investment Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-400
Closed -$5K – 979
2019
Q1 		$5K Hold
400
– – ﹤0.01% 773
2018
Q4 		$4K Hold
400
– – ﹤0.01% 829
2018
Q3 		$6K Buy
+400
New +$5.95K ﹤0.01% 833

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advantage Investment Management's FPRX Position: Q2 2019 in Review

Advantage Investment Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2019, closing a stake of 400 shares — an estimated $5K sold.

Advantage Investment Management first reported a position in FPRX in Q3 2018 and held it in 3 quarters. The position peaked at $6K in Q3 2018. 114 funds tracked by Wall St. Rank hold FPRX as of Q2 2019.

  • Advantage Investment Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Advantage Investment Management sold 400 Five Prime Therapeutics, Inc. shares in Q2 2019, an estimated $5K.
  • Advantage Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2018 and held it in 3 quarters.
  • Advantage Investment Management's Five Prime Therapeutics, Inc. position peaked at $6K in Q3 2018.
  • 114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2019.

Based on Advantage Investment Management's 13F filing for Q2 2019, filed 30 Jul 2019.